Share on LinkedInShare on LinkedIn

ARTICLE · 05 MARCH 2025

Patent Wars: The Global Patent Battle Over Vyndamax

Naik Naik & Company
Naik Naik & Company
Contributor
Naik Naik & Company

Naik Naik & Company

The firm Naik Naik & Co is a full-service law firm Headquartered in Mumbai with affiliate offices...

View firm profile
Explore more from Naik Naik & Company

Recently, Madras High Court pronounced an order relating to an ongoing patent dispute in the United States. Pfizer, a pharmaceutical giant has patented "VYNDAMAX" aka "TAFAMIDIS", a drug used to treat a heart condition.

IndiaIntellectual Property

Recently, Madras High Court pronounced an order relating to an ongoing patent dispute in the United States. Pfizer, a pharmaceutical giant has patented "VYNDAMAX" aka "TAFAMIDIS", a drug used to treat a heart condition called "Transthyretin Amyloid Cardiomyopathy (ATTR-CM)" in the United States. This case centres around Cipla and Zenara (Hikma) filing ANDAs with the United States Food & Drug Administration (FDA) for the approval to sell generic versions of the drug Vyndamax. Later on, Pfizer filed a suit in the US District Court at Delaware claiming that the generic versions of the drug infringe upon its U.S. patent rights.

Why Is India Involved?

According to Pfizer, Softgel Healthcare Private Limited, an Indian company and apparently a business partner of Cipla and Zenara possesses certain set of documents that can help Pfizer to prove their case in the US Delaware Court. Further to prove its allegations, Pfizer requested the US District Court to issue a Letter

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from